Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Winckelmann, Anni A ^a   Munk Petersen, Lærke V ^a   Rasmussen, Thomas A ^a   Melchjorsen, Jesper ^a   Hjelholt, Thomas J ^a   Montefiori, David ^b   Østergaard, Lars ^a   Søgaard, Ole S ^a   Tolstrup, Martin ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PNEUMOCOCCUS VACCINE; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; VIRUS DNA;

ADJUVANT THERAPY; ADULT; ANTIBODY SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CRYOPRESERVATION; DEGRANULATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; UPREGULATION; VIRUS IMMUNITY; VIRUS LATENCY; VIRUS LOAD;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COMPARTMENTATION; DISEASE RESERVOIRS; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNITY; IMMUNOLOGIC MEMORY; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; PHENOTYPE; PROVIRUSES; SPECIES SPECIFICITY; TOLL-LIKE RECEPTOR 9; VIRAL LOAD;

EID: 84876867629     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062074     Document Type: Article

References (51)

1. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. ProcNatlAcadSciUSA 105: 3879-3884.
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
3. Davey RT Jr, Bhat N, Yoder C, Chun TW, Mecalf JA, et al. (1999) HIV-1 and T-cell dynamics after interruption of higly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. ProcNatlAcadSciUSA 96: 15109-15114.
4. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. NEnglJMed 355: 2283-2296.
5. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature medicine 15: 893-900.
6. Chun TW, Engel D, Berrey MM, Shea T, Corey L, et al. (1998) Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 95: 8869-8873.
7. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
8. Wyl V, Gianella S, Fischer M, Niederoest B, Kuster H, et al. (2011) Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One 6: 15.
9. Murray JM, McBride K, Boesecke C, Bailey M, Amin J, et al. (2012) Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS 26: 543-550.
10. Chege D, Kovacs C, la Porte C, Ostrowski M, Raboud J, et al. (2012) Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial. AIDS 26: 167-174.
11. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, et al. (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106: 9403-9408.
12. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, et al. (2010) The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7.
13. Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, et al. (2012) The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 26: 1885-1894.
14. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS research and human retroviruses 25: 207-212.
15. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, et al. (2005) IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 115: 128-137.
16. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, et al. (2001) Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98: 3006-3015.
17. Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, et al. (2011) Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 85: 6060-6064.
18. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, et al. (2010) Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 6: e1000917.
19. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, et al. (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36: 491-501.
20. Valor L, Navarro J, Carbone J, Rodriguez-Sainz C, Gil J, et al. (2008) Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy. Vaccine 26: 2738-2745.
21. Persaud D, Luzuriaga K, Ziemniak C, Muresan P, Greenough T, et al. (2011) Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS 25: 2227-2234.
22. Harrer E, Bauerle M, Ferstl B, Chaplin P, Petzold B, et al. (2005) Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 10: 285-300.
23. Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, et al. (1999) Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature medicine 5: 651-655.
24. Hedayat M, Netea MG, Rezaei N, (2011) Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infect Dis 11: 702-712.
25. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, et al. (2004) CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24: 693-701.
26. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, et al. (2005) CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 19: 1473-1479.
27. Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, et al. (2004) Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22: 3136-3143.
28. Sogaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, et al. (2010) Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. ClinInfectDis 51: 42-50.
29. Offersen R, Melchjorsen J, Paludan SR, Ostergaard L, Tolstrup M, et al. (2012) TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults. Hum Vaccin Immunother 8: 8.
30. Lahoud MH, Ahmet F, Zhang JG, Meuter S, Policheni AN, et al. (2012) DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci U S A 109: 16270-16275.
31. Scheller C, Ullrich A, McPherson K, Hefele B, Knoferle J, et al. (2004) CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. JBiolChem 279: 21897-21902.
32. Scheller C, Ullrich A, Lamla S, Dittmer U, Rethwilm A, et al. (2006) Dual activity of phosphorothioate CpG oligodeoxynucleotides on HIV: reactivation of latent provirus and inhibition of productive infection in human T cells. AnnNYAcadSci 1091: 540-547.
33. Sulkowski MS, Chaisson RE, Karp CL, Moore RD, Margolick JB, et al. (1998) The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. The Journal of infectious diseases 178: 1642-1648.
34. Rotchford K, Strum AW, Wilkinson D, (2000) Effect of coinfection with STDs and of STD treatment on HIV shedding in genital-tract secretions: systematic review and data synthesis. Sexually transmitted diseases 27: 243-248.
35. Agrawal S, Martin RR, (2003) Was induction of HIV-1 through TLR9? Journal of immunology 171: 1621; author reply 1621-1622.
36. Offersen R, Melchjorsen J, Paludan SR, Ostergaard L, Tolstrup M, et al. (2012) TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults. Hum Vaccin Immunother 8: 1042-1047.
37. Malik AN, Shahni R, Rodriguez-de-Ledesma A, Laftah A, Cunningham P, (2011) Mitochondrial DNA as a non-invasive biomarker: accurate quantification using real time quantitative PCR without co-amplification of pseudogenes and dilution bias. Biochem Biophys Res Commun 412: 1-7.
38. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, et al. (2010) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24: 2803-2808.
39. Bernasconi NL, Traggiai E, Lanzavecchia A, (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298: 2199-2202.
40. Hu X, Hong K, Zhao C, Zheng Y, Ma L, et al. (2012) Profiles of neutralizing antibody response in chronically HIV-1 clade B' infected former plasma donors naive to ART from China. J Gen Virol 18: 18.
41. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, et al. (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. JImmunol 168: 4531-4537.
42. Barblu L, Machmach K, Gras C, Delfraissy JF, Boufassa F, et al. (2012) Plasmacytoid dendritic cells from HIV controllers produce IFN-alpha and differentiate into functional killer pDC under HIV activation. The Journal of infectious diseases 12: 12.
43. Manion M, Rodriguez B, Medvik K, Hardy G, Harding CV, et al. (2012) Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One 7: 24.
44. Dalod M, Hamilton T, Salomon R, Salazar-Mather TP, Henry SC, et al. (2003) Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. J Exp Med 197: 885-898.
45. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, et al. (2004) TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21: 107-119.
46. Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS, (1999) Re-emergence of HIV after stopping therapy. Nature 401: 874-875.
47. Okulicz JF, Lambotte O, (2011) Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS 6: 163-168.
48. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, et al. (2007) HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 104: 6776-6781.
49. O'Connell KA, Han Y, Williams TM, Siliciano RF, Blankson JN, (2009) Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J Virol 83: 5028-5034.
50. Critchfield JW, Young DH, Hayes TL, Braun JV, Garcia JC, et al. (2008) Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status. PLoS One 3: 30.
51. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789.